Izvorni znanstveni članak
https://doi.org/10.18054/pb.v120i2-3.6703
Fibrinolytic parameters under ischemic stroke with diabetes mellitus combination
Olha Kravchenko
; Taras Shevchenko National University of Kyiv
Nataliia Raksha
Tetiana Halenova
orcid.org/0000-0003-3817-6485
Tetiana Ishchuk
Tetiana Vovk
Mariia Tymoshenko
orcid.org/0000-0001-5390-3092
Oleksii Savchuk
Liudmila Ostapchenko
Sažetak
Abstract
Background: Fibrinolysis and thrombosis alterations include important parts of stroke pathophysiology. At the same time fibrinolytic system disorders are a common feature of patients with metabolic syndrome and diabetes. So it may increase the possibility of developing atherosclerotic lesions and occlusive intravascular thrombi. The present study investigated the influence of type 2 diabetes mellitus presence on the indicators of fibrinolytic parameters (plasminogen activator inhibitor 1 (PAI-1), tissue-type plasminogen activator (tPA) content, streptokinase-activated plasminogen and α2-antiplasmin activities, euglobulin clot lysis time (ECLT) and Hageman-factor-dependent fibrinolysis time) under ischemic stroke (IS).
Materials and methods: Participants were 87 subjects with IS, 22 of them had diabetes mellitus. Blood samples besides for aforementioned parameters were analyzed for glucose and glycosylated haemoglobin content.
Results: The research established increase of plasma PAI-1 and tPA levels, ECLT, Hageman-factor-dependent fibrinolysis time in IS and IS with diabetes mellitus patient groups in comparison with the control. PAI-1 concentration in plasma was positively correlated with both lysis time tests but tPA content was negative correlated with glucose level and PAI-1 for only IS patients. But there was a high negative correlation between tPA and ECLT as well as Hageman-factor-dependent fibrinolysis time for both investigated IS forms.
Conclusions: The results showed important differences in the characteristics of the fibrinolytic mechanism in IS patients compared with healthy population. The major differences were elevated PAI-1 and t-PA contents and prolonged ECLT in IS patients but no significant differences in these parameters were observed between the patients with IS and IS with diabetes.
Ključne riječi
α2-antiplasmin; type 2 diabetes mellitus; euglobulin clot lysis time; plasminogen activator inhibitor 1; tissue-type plasminogen activator
Hrčak ID:
225310
URI
Datum izdavanja:
16.9.2019.
Posjeta: 1.029 *